Upadacitinib CAS NO.1310726-60-3

World Pharmaceutical (Anhui) Co., Ltd. is a joint-stock company, consisting of Haikang Pharmaceutical (Anhui) Co., Ltd., Anqing World Chemical Co., Ltd., Anqing Proud Import & Export Co., Ltd. and Anqing Xuanyu Medical & Technology Co., Ltd. Anhui Haikang Pharmaceutical Co., Ltd. was established in 2009 and located in High-tech industry park, Anqing City, Anhui Province---a famous historical and cultural city in China, adjacent to SINOPEC Anqing Branch. This industry park has been declared as a national chemical industry park, providing strong impetus and solid guarantee for the future development of us. As a production base, Anhui Haikang provides sufficient high-quality pharmaceutical and chemical products for us

Upatinib is an oral JAK1 inhibitor used in the treatment of rheumatoid arthritis, psoriasis arthritis and other diseases. JAK kinase, is a family of non-receptor tyrosine kinases, which has found four members, namely JAK1, JAK2, JAK3 and TYK1. The substrate of the JAK is STAT,, namely, signal transconductors and transcription activators. STAT occurs after being phosphorylated by JAK, Then pass through the nuclear membrane into the nucleus to regulate the expression of related genes, The signaling pathway is called the JAK-STAT pathway Chemicalbook, Thus JAK plays an important role in the pathophysiology of immunomediated diseases, Can be used to treat some autoimmune diseases such as treating atopic dermatitis, rheumatoid arthritis, Psoriasis, ulcerative colitis, etc., In 2017, the first rheumatoid arthritis orally targeted drug JAK kinase inhibitor, —— tofinib, in 2017, Is the first JAK kinase inhibitor approved for the treatment of rheumatoid arthritis, It can prevent cellular signal transduction of inflammatory cytokines that can lead to rheumatoid arthritis.

Upadacitinib (Upadacitinib) is a JAK1 inhibitor, which has shown good efficacy in clinical trials for the treatment of a variety of autoimmune diseases and inflammatory diseases.Upadacitinib (ABT-494) is a potent and selective Janus kinase (JAK) 1 inhibitor with an IC50 of 43 nM, being developed for the treatment of several autoimmune disorders.